FDA Issues Class II Recall of Generic Triple-Action Blood Pressure Medication
仅事实

FDA Issues Class II Recall of Generic Triple-Action Blood Pressure Medication

摘要

The U.S. Food and Drug Administration has recalled two lots of a generic blood pressure tablet containing olmesartan medoxomil, amlodipine and hydrochlorothiazide because the tablets may not dissolve properly, potentially reducing effectiveness.

The U.S. Food and Drug Administration announced a class II recall of a generic combination blood pressure medication after discovering that the tablets may not dissolve correctly, which could make the drug less effective. The medication, which combines olmesartan medoxomil, amlodipine and hydrochlorothiazide, is used to lower high blood pressure and reduce the risk of heart attack and stroke.

Macleods Pharma is recalling two nationwide-distributed lots: about 3,500 bottles of the 30-count version (lot 12251163A) and roughly 200 bottles of the 90-count version (lot 12251163B), both bearing an expiration date of May 31, 2027.

The FDA classifies the recall as class II, indicating that the issue could cause temporary or medically reversible health effects, though serious complications are considered unlikely. The agency advises patients to continue taking the medication unless the manufacturer provides different instructions, and to consult a doctor or pharmacist before stopping the drug.

Patients should check prescription bottle labels for the manufacturer’s name and lot numbers, and contact their pharmacy or healthcare provider with any concerns.

来源

Yahoo

继续阅读——免费

创建免费账户以关注新闻。无需银行卡。